证券代码：002932 证券简称：明德生物 公告编号：2025-030 武汉明德生物科技股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 3、会议召开方式： 本次股东大会采取现场投票、网络投票相结合的方式召开。 （1）现场投票：股东本人出席现场会议或者通过授权委托书委托他人出席 现场会议； （1）现场会议：2025年5月16日（星期五）14:00开始 （2）网络投票时间：2025年5月16日 其中通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月 16日（星期五）上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为：2025年5月16日（星期五）9:15-15:00期间 的任意时间。 2、现场会议召开地点：武汉市东湖新技术开发区九龙中路77号武汉明德生 物科技产业园1 ...

北 京 大 成 （ 武 汉 ） 律 师 事 务 所 关 于 武 汉 明 德 生 物 科 技 股 份 有 限 公 司 2024 年 年 度 股 东 大 会 的 法 律 意 见 书 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范性文 件的要求，北京大成（武汉）律师事务所（以下简称"本所"）接受武汉明德生物 科技股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2024 年年度 股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序及表决结果发表法律意见，并不对本次股东大会所审 议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法律意见书随 本次股东大会其他信息披露资料一并公告。 北 京 大 成 （ 武 汉 ） 律 师 事 务 所 www.dentons.cn 武汉市江岸区建设大道 718 号浙商大厦 10 层（430015） 10/F, Zheshang ...

Company Overview - Mingde Biological Technology Co., Ltd. primarily engages in the research, development, production, sales, and service of in vitro diagnostic reagents and diagnostic instruments [1] - The company's main products and services cover three major areas: in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of Q1 2025, the company reported operating revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, reflecting a year-on-year decline of 111.43% [1] - The gross profit margin stood at 16.37% [1] Market Position - The company's closing stock price on May 7 was 18.72 yuan, down 1.58%, with a rolling price-to-earnings (PE) ratio of 112.17 times [1] - The total market capitalization is 4.353 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 49.02 times, with a median of 36.25 times, placing Mingde Biological at the 107th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders was 25,981, a decrease of 717 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Industry Recognition - In December 2022, a hospital in Hubei Province utilizing the company's information solutions won the Best Solution Award for Smart Chest Pain Center at the China Cardiovascular Health Conference, marking it as the only county-level hospital to receive this award [1]

前十大流通股东累计持有： 4471.1万股，累计占流通股比： 28.64%，较上期变化： 83.49万股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 陈莉莉 | 1572.97 | 10.08 | 不变 | | 王颖 | 897.92 | 5.75 | 不变 | | 陈鑫涛 | 429.63 | 2.75 | -16.00 | | 广发价值核心混合A | 284.62 | 1.82 | 不变 | | 中国平安人寿保险股份有限公司-分红-个险分红 | 265.16 | 1.70 | 新进 | | 易方达中证红利ETF | 240.56 | 1.54 | 15.83 | | 中国平安人寿保险股份有限公司-自有资金 | 219.53 | 1.41 | -0.56 | | 招商中证红利ETF | 194.69 | 1.25 | 29.49 | | 周琴 | 186.02 | 1.19 | -2.05 | | 融通健康产业灵活配置混合A/B | 180.00 | 1.15 | -83.28 | | 较上个报告期退出前十大股东 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉明德生物科技股份有限公司（以下简称"公司"）第四届董事会第二十 次会议于 2025 年 4 月 29 日以现场及通讯相结合的方式在公司会议室召开，会议 通知已于 2025 年 4 月 25 日以电子邮件、电话通讯等形式发出。本次会议应到董 事 7 名，实际出席公司会议的董事 7 名，会议由公司董事长陈莉莉女士主持，公 司监事、高级管理人员列席了本次会议，会议的召集和召开符合《中华人民共和 国公司法》（以下简称"公司法"）等法律法规及公司章程的规定。 证券代码：002932 证券简称：明德生物 公告编号：2025-028 武汉明德生物科技股份有限公司 第四届董事会第二十次会议决议公告 二、董事会会议审议情况 1、审议并通过《2025 年第一季度报告》 表决结果：同意票数为 7 票，反对票数为 0 票，弃权票数为 0 票。 本议案已经公司审计委员会全体审议通过。 《2025 年第一季度报告》具体内容 2025 年 4 月 30 日刊登在《证券时报》 和巨潮资讯网（http://www.cn ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥69,960,271.60, representing a 14.76% increase compared to ¥60,963,422.30 in the same period last year[3] - The net profit attributable to shareholders was -¥3,662,988.06, a decline of 111.43% from ¥32,052,081.48 in the previous year[3] - Basic and diluted earnings per share were both -¥0.02, down 114.29% from ¥0.14 in the previous year[3] - Net profit for the current period was a loss of ¥3,405,173.99, compared to a profit of ¥28,108,162.20 in the previous period, indicating a significant decline[19] Cash Flow and Operating Activities - The net cash flow from operating activities was -¥30,524,488.33, a decrease of 166.81% compared to ¥45,688,082.68 in the same period last year[3] - Cash inflow from operating activities totaled ¥154,356,495.64, a decrease from ¥294,315,194.08 in the previous period[20] - Cash received from sales of goods and services was ¥146,015,819.62, down 36.40% from ¥229,599,558.61 in the previous year, indicating a slowdown in cash collection[8] - The total cash and cash equivalents at the end of the period decreased to $236.99 million from $884.23 million, reflecting a substantial reduction[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,499,402,061.63, a decrease of 1.42% from ¥6,593,078,595.90 at the end of the previous year[3] - Current assets total 4,306,916,741.27 RMB, an increase from 2,397,670,406.85 RMB at the beginning of the period[14] - Total liabilities include short-term borrowings of 3,000,000.00 RMB and accounts payable of 248,241,215.03 RMB[14] - The total liabilities decreased from ¥574,401,155.88 to ¥499,733,047.11, reflecting a reduction in financial obligations[15] Operating Costs and Expenses - The company's operating costs increased by 60.69% to ¥58,506,453.08, primarily due to revenue growth and a decline in gross margin[8] - Total operating costs increased to ¥114,191,703.22, up 9.6% from ¥104,189,807.01 in the previous period, with operating costs specifically rising from ¥36,409,334.65 to ¥58,506,453.08[17][18] - Research and development expenses were reported at ¥24,550,271.02, down from ¥27,181,929.06 in the previous period, indicating a reduction in investment in innovation[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,981[10] - The top shareholder, Chen Lili, holds 27.06% of shares, totaling 62,918,895 shares[10] - The company has repurchased 13,034,741 shares, representing 5.61% of the total share capital[11] Credit and Impairment - The company reported a significant increase in credit impairment losses, amounting to ¥14,258,490.11, a rise of 307.19% compared to -¥6,881,817.36 in the previous year[8] - The company experienced a credit impairment loss of ¥14,258,490.11, compared to a gain of -¥6,881,817.36 in the previous period, highlighting increased credit risk[18] Government Subsidies - The company received government subsidies amounting to ¥23,500.00, which were significantly lower compared to previous periods[5] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[23]

Company Overview - Mingde Biological Technology Co., Ltd. focuses on the research, production, sales, and service of in vitro diagnostic reagents and instruments, covering three main areas: in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] - The company achieved a revenue of 350 million yuan in 2024, representing a year-on-year decrease of 53.30%, with a net profit of 74.52 million yuan, down 0.54% year-on-year, and a gross profit margin of 53.89% [1] Market Performance - As of April 28, Mingde Biological's stock closed at 17.52 yuan, down 3.15%, with a rolling price-to-earnings (PE) ratio of 54.67 times and a total market capitalization of 4.074 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Mingde Biological at the 93rd position in the industry ranking [1][2] Capital Flow - On April 28, the net outflow of main funds for Mingde Biological was 688,300 yuan, although the overall trend over the past five days showed a net inflow of 14.56 million yuan [1]

近期明德生物（002932）发布2024年年报，证券之星财报模型分析如下： 从单季度数据来看，第四季度营业总收入为1.24亿元，同比上升0.68%；归母净利润为-641.88万元，同 比上升90.88%；扣非净利润为-1.01亿元，同比上升40.45%。虽然第四季度营收略有增长，但扣非净利 润仍为负值，且全年整体表现不佳。 费用与利润率 经营概况 明德生物发布的2024年年报显示，公司全年营业总收入为3.5亿元，同比下降53.3%。归母净利润为 7451.96万元，同比下降0.54%。扣非净利润为-1.4亿元，同比下降12.74%。尽管归母净利润降幅较小， 但扣非净利润的大幅下滑表明公司主营业务盈利能力减弱。 单季度表现 总体来看，明德生物2024年的财务表现不尽如人意，主营收入和利润均出现不同程度的下滑，费用占比 上升明显。公司需进一步优化成本控制，提升主营业务盈利能力，以应对未来的市场挑战。 货币资金：4.94亿元，同比下降51.37% 应收账款：7.64亿元，同比下降36.79% 有息负债：729.63万元，同比下降76.39% 每股净资产：25.06元，同比下降3.31% 每股经营性现金流：-0.37 ...

每经记者 王琳 每经编辑 马子卿 4月24日晚间，明德生物（SZ002932，股价18.09元，市值42.06亿元）发布2024年年报，公司在2024年 实现营业收入3.50亿元，同比下降53.30%，其扣非净利润则连续第二年录得亏损。这样的业绩也使得明 德生物与"扣非净利润为负且营业收入不足3亿元"的"退市预警线"距离被大幅拉近。 值得一提的是，明德生物在2024年末的可分配利润甚至超过其总市值（按4月24日收盘价计算）。在这 样的情况下，明德生物再次回归高分红，宣布拟向全体股东每10股派发现金红利12元（含税），分红金 额达2.63亿元。以4月24日收盘价计算，其股息率高达近7%。 年报显示，明德生物在2024年实现营业收入和归母净利润分别为3.5亿元和7452万元，同比分别下降 53%和0.54%。此外，公司扣非净利润则录得亏损1.4亿元，连续第二年亏损，亏损额较2023年也有所扩 大。 分季度来看，明德生物在2024年第四季度的营业收入为1.24亿元，较2023年同期略有增长，其在2024年 第四季度的归母净利润和扣非净利润也较上年同期均明显减亏。 明德生物表示，公司2024年度营业收入大幅下降以及扣 ...